{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:27:32Z","timestamp":1791145652286,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,11,24]],"date-time":"2006-11-24T00:00:00Z","timestamp":1164326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2007,3,29]]},"DOI":"10.1007\/s00198-006-0286-8","type":"journal-article","created":{"date-parts":[[2006,11,27]],"date-time":"2006-11-27T17:27:15Z","timestamp":1164648435000},"page":"681-685","source":"Crossref","is-referenced-by-count":120,"title":["Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases"],"prefix":"10.1007","volume":"18","author":[{"given":"K.","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"Tanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Qvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,11,24]]},"reference":[{"key":"286_CR1","first-page":"1","volume-title":"Anatomy and biology of bone matrix and cellular elements. Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"R Baron","year":"2003","unstructured":"Baron R (2003) Anatomy and biology of bone matrix and cellular elements. Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 1\u20138"},{"issue":"(Suppl 1)","key":"286_CR2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01621884","volume":"3","author":"TJ Martin","year":"1993","unstructured":"Martin TJ (1993) Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121\u2013125","journal-title":"Osteoporos Int"},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/0378-5122(96)01015-8","volume":"23 Suppl","author":"HK Vaananen","year":"1996","unstructured":"Vaananen HK, Harkonen PL (1996) Estrogen and bone metabolism. Maturitas 23 Suppl:S65\u2013S69","journal-title":"Maturitas"},{"key":"286_CR4","first-page":"115","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115\u2013137","journal-title":"Endocr Rev"},{"key":"286_CR5","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508\u20131514","journal-title":"Science"},{"key":"286_CR6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"P Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526\u20131536","journal-title":"J Bone Miner Res"},{"key":"286_CR7","first-page":"2363","volume":"84","author":"P Ravn","year":"1999","unstructured":"Ravn P, Hosking D, Thompson D et al (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363\u20132368","journal-title":"J Clin Endocrinol Metab"},{"key":"286_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","volume":"24","author":"P Ravn","year":"1999","unstructured":"Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237\u2013244","journal-title":"Bone"},{"key":"286_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lab.2005.03.016","volume":"146","author":"G Holzer","year":"2005","unstructured":"Holzer G, Noske H, Lang T (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13\u201317","journal-title":"J Lab Clin Med"},{"key":"286_CR10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","volume":"63","author":"BJ Gertz","year":"1998","unstructured":"Gertz BJ, Clemens JD, Holland SD et al (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102\u2013106","journal-title":"Calcif Tissue Int"},{"key":"286_CR11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","volume":"14","author":"HW Woitge","year":"1999","unstructured":"Woitge HW, Pecherstorfer M, Li Y (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792\u2013801","journal-title":"J Bone Miner Res"},{"key":"286_CR12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","volume":"26","author":"S Christgau","year":"2000","unstructured":"Christgau S, Bitsch-Jensen O, Hanover BN et al (2000) Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505\u2013511","journal-title":"Bone"},{"key":"286_CR13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1359\/jbmr.2000.15.7.1337","volume":"15","author":"JM Halleen","year":"2000","unstructured":"Halleen JM, Alatalo SL, Suominen H et al (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337\u20131345","journal-title":"J Bone Miner Res"},{"key":"286_CR14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jcb.20835","volume":"98","author":"B Kirstein","year":"2006","unstructured":"Kirstein B, Chambers TJ, Fuller K (2006) Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem 98:1085\u20131094","journal-title":"J Cell Biochem"},{"key":"286_CR15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1359\/JBMR.040302","volume":"19","author":"S Schaller","year":"2004","unstructured":"Schaller S, Henriksen K, Sveigaard C et al (2004) The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144\u20131153","journal-title":"J Bone Miner Res"},{"key":"286_CR16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9440(10)62269-9","volume":"166","author":"MA Karsdal","year":"2005","unstructured":"Karsdal MA, Henriksen K, Sorensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467\u2013476","journal-title":"Am J Pathol"},{"key":"286_CR17","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1210\/en.2005-0333","volume":"146","author":"AJ Koh","year":"2005","unstructured":"Koh AJ, Demiralp B, Neiva KG et al (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584\u20134596","journal-title":"Endocrinology"},{"key":"286_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","volume":"11","author":"TJ Martin","year":"2005","unstructured":"Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76\u201381","journal-title":"Trends Mol Med"},{"key":"286_CR19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11914-003-0008-5","volume":"1","author":"AA Reszka","year":"2003","unstructured":"Reszka AA, Rodan GA (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1:45\u201352","journal-title":"Curr Osteoporos Rep"},{"key":"286_CR20","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","volume":"20","author":"A Nenonen","year":"2005","unstructured":"Nenonen A, Cheng S, Ivaska KK et al (2005) Serum TRACP 5b Is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804\u20131812","journal-title":"J Bone Miner Res"},{"key":"286_CR21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831","journal-title":"N Engl J Med"},{"key":"286_CR22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-006-0026-2","volume":"8","author":"NA Hamdy","year":"2006","unstructured":"Hamdy NA (2006) Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep 8:50\u201354","journal-title":"Curr Rheumatol Rep"},{"key":"286_CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","volume":"34","author":"RA Hannon","year":"2004","unstructured":"Hannon RA, Clowes JA, Eagleton AC et al (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187\u2013194","journal-title":"Bone"},{"key":"286_CR24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-004-1819-7","volume":"16","author":"R Tahtela","year":"2005","unstructured":"Tahtela R, Seppanen J, Laitinen K et al (2005) Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 16:1109\u20131116","journal-title":"Osteoporos Int"},{"key":"286_CR25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1532-5415.2004.52218.x","volume":"52","author":"H Hansdottir","year":"2004","unstructured":"Hansdottir H, Franzson L, Prestwood K et al (2004) The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779\u2013783","journal-title":"J Am Geriatr Soc"},{"key":"286_CR26","unstructured":"Hannon RA, Clack G, Gallager N et al (2005) The effect of AZ0530, a highly selective SRC inhibitor, on bone turnover in healthy males. European Calcified Tissue Society Conference 2005 [Abstract nb OC042]"},{"key":"286_CR27","unstructured":"Capparelli C, Morony S, Warmington KS et al (2000) Pharmacologic Effects of a Single Treatment with Osteoprotegerin (OPG) on Bone Remodeling and Bone Density in Normal Rats. J Bone Miner Res 15 [Suppl 1], abstract 1132"},{"key":"286_CR28","unstructured":"Kostenuik P, Warmington KS, Grisanti M et al (2005) RANKL Inhibition with AMG 162, a Fully Human MAb, Causes Sustained Suppression of Bone Resorption and Increased BMD in Knockin Mice Expressing Humanized RANKL. J Bone Miner Res 20[Suppl 1], abstract SU304"},{"key":"286_CR29","doi-asserted-by":"crossref","first-page":"44975","DOI":"10.1074\/jbc.M303905200","volume":"278","author":"MA Karsdal","year":"2003","unstructured":"Karsdal MA, Hjorth P, Henriksen K et al (2003) Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975\u201344987","journal-title":"J Biol Chem"},{"key":"286_CR30","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)63712-1","volume":"164","author":"K Henriksen","year":"2004","unstructured":"Henriksen K, Gram J, Schaller S et al (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing Autosomal Dominant Osteopetrosis type II (ADOII). Am J Pathol 164:1537\u20131545","journal-title":"Am J Pathol"},{"key":"286_CR31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/8756-3282(93)90316-3","volume":"14","author":"J Bollerslev","year":"1993","unstructured":"Bollerslev J, Marks SC Jr, Pockwinse S et al (1993) Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865\u2013869","journal-title":"Bone"},{"key":"286_CR32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1373\/clinchem.2003.029355","volume":"50","author":"SL Alatalo","year":"2004","unstructured":"Alatalo SL, Ivaska KK, Waguespack SG et al (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883\u2013890","journal-title":"Clin Chem"},{"key":"286_CR33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jmg.2005.036673","volume":"43","author":"A Fattore Del","year":"2005","unstructured":"Del Fattore A, Peruzzi B, Rucci N et al (2005) Clinical, genetic and cellular analysis of forty-nine osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315\u2013325","journal-title":"J Med Genet"},{"key":"286_CR34","first-page":"476","volume":"74","author":"A Schlemmer","year":"1992","unstructured":"Schlemmer A, Hassager C, Jensen SB et al (1992) Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476\u2013480","journal-title":"J Clin Endocrinol Metab"},{"key":"286_CR35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","volume":"31","author":"P Qvist","year":"2002","unstructured":"Qvist P, Christgau S, Pedersen BJ et al (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57\u201361","journal-title":"Bone"},{"key":"286_CR36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00041552-199907000-00005","volume":"8","author":"SM Hart","year":"1999","unstructured":"Hart SM, Eastell R (1999) Biochemical markers of bone turnover. Curr Opin Nephrol Hypertens 8:421\u2013427","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"286_CR37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ar.1092220303","volume":"222","author":"DJ Simmons","year":"1988","unstructured":"Simmons DJ, Menton DN, Russell JE et al (1988) Bone cell populations and histomorphometric correlates to function. Anat Rec 222:228\u2013236","journal-title":"Anat Rec"},{"key":"286_CR38","first-page":"1027","volume":"23","author":"JM Halleen","year":"2003","unstructured":"Halleen JM (2003) Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23:1027\u20131029","journal-title":"Anticancer Res"},{"key":"286_CR39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/jm030317k","volume":"47","author":"PA Ple","year":"2004","unstructured":"Ple PA, Green TP, Hennequin LF et al (2004) Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 47:871\u2013887","journal-title":"J Med Chem"},{"key":"286_CR40","first-page":"1","volume":"52","author":"C Meier","year":"2006","unstructured":"Meier C, Meinhardt U, Greenfield JR et al (2006) Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget\u2019s disease. Clin Lab 52:1\u201310","journal-title":"Clin Lab"},{"key":"286_CR41","doi-asserted-by":"crossref","first-page":"28370","DOI":"10.1074\/jbc.M502469200","volume":"280","author":"J Ljusberg","year":"2005","unstructured":"Ljusberg J, Wang Y, Lang P et al (2005) Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 280:28370\u201328381","journal-title":"J Biol Chem"},{"key":"286_CR42","unstructured":"Rissanen J, Suutari S, Ylonen S et al (2005) The Ratio of Osteoclast Activity\/Osteoclast Number (CTX\/TRACP 5b) Improves the Interpretation of the Effects of Anti-Resorptive Treatments in Human Osteclast Cultures. J Bone Miner Res 20[Suppl 1], abstract SU290"},{"key":"286_CR43","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226","journal-title":"N Engl J Med"},{"key":"286_CR44","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"286_CR45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S8756-3282(03)00236-9","volume":"33","author":"RP Heaney","year":"2003","unstructured":"Heaney RP (2003) Is the paradigm shifting? Bone 33:457\u2013465","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-006-0286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-006-0286-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-006-0286-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:00:47Z","timestamp":1558638047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-006-0286-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,24]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,3,29]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1007\/s00198-006-0286-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,24]]}}}